Correspondence 0001564590-22-039680 from Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc.
Date: Dec. 23, 2022 · CIK: 0001835022 · Accession: 0001564590-22-039680
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268482
Letter
Re: Coya Therapeutics, Inc.
coya-corresp.DOCX.htm
December 23, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-268482
Acceleration Request
Requested Date:December 28, 2022
Requested Time:4:00 p.m. Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representative of the underwriters, hereby join in the request of Coya Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time (US), on December 28, 2022, or at such later time as the Company or its outside counsel, Lowenstein Sandler LLP, may request via a telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 355 copies of the Preliminary Prospectus dated December 12, 2022 through the date hereof, to underwriters, dealers, institutions and others.
The undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Acting on behalf of itself and the several Underwriters
Show Raw Text
CORRESP
1
filename1.htm
coya-corresp.DOCX.htm
December 23, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Coya Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-268482
Acceleration Request
Requested Date:December 28, 2022
Requested Time:4:00 p.m. Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representative of the underwriters, hereby join in the request of Coya Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time (US), on December 28, 2022, or at such later time as the Company or its outside counsel, Lowenstein Sandler LLP, may request via a telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 355 copies of the Preliminary Prospectus dated December 12, 2022 through the date hereof, to underwriters, dealers, institutions and others.
The undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Acting on behalf of itself and the several Underwriters
CHardan capital markets, llc
By: /s/ Shai Gerson
Name:Shai Gerson
Title:
Managing Partner of Capital Markets